Nordic Nanovector Starting Pivotal Trial With Lead Asset Betalutin In R/R FL

 
• By Sten Stovall

Norwegian biotech is starting PARADIGME Phase IIb trial testing Betalutin in follicular lymphoma.

Leukemia cell (blast cell)
Betalutin is a potential new targeted treatment for patients with non-Hodgkin’s lymphoma • Source: Shutterstock

More from Anticancer

More from Therapy Areas